BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Beximco Pharmaceuticals Appointments Faheemul Huq to the Board


4/4/2013 9:52:01 AM

April 4, 2013 -- Beximco Pharmaceuticals Limited (“BPL” or “Company”; AIM Symbol: BXP) announces the resignation of Ahsanul Karim and the appointment to the Board of Directors of Faheemul Huq as a Non-Executive Director of the Company.

Mr Karim’s resignation was accepted by the Board at a Board meeting on 3 April 2013, becoming effective immediately. Mr Karim resigned for personal reasons and the board wishes to thank Mr Karim for the guidance and contribution given while a director of the Company.

At the same time the board would like to welcome Mr Huq to the Board. Mr Huq (48) is a Barrister-at-Law in England and Wales, an Advocate to the Supreme Court of Bangladesh and a member of the Bangladesh Supreme Court and Dhaka Bar Associations. He is working at the law firm of Huq and Company where he advises local and international companies on a variety of legal subjects including Corporate law, Corporate Governance and International Arbitration. Mr Huq received LLB (Hon’s) from both the University of Dhaka, Bangladesh and Wolverhampton, UK.

Mr Huq has been appointed for an initial term of three years, subject to shareholder approval at the Company’s next AGM. As one of the independent directors, Mr Huq will take over the role of Chairman of the reconstituted Audit Committee with immediate effect.

Additional information about Mr Huq required under Schedule 2 (g) of the AIM Rules:

Current Directorships:

AB Bank Limited

Bangladesh Export Import Company Limited

There is no further information required to be disclosed under Schedule 2 (g) of the AIM Rules.

For further enquiries please contact:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 8618220-1, Ext 10140

Libertas Capital Corporate Finance (Nomad)

Thilo Hoffmann

Tel: +44 (0)20 7569 9650

Daniel Stewart & Company (Broker)

Paul Shackleton

James Thomas

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway / Susan Stuart / Victoria Foster-Mitchell

Tel: +44 (0)20 7269 7169

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

Beximco Pharma’s state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES